#Bharat Biotech Vaccine

[thenewsfactsnow]

Bharat Biotech and University of Sydney Sign MoU to Advance Academic and Vaccine Research Collaboration

Hyderabad, India, and Sydney, Australia – 28th November 2023 – Bharat Biotech International Limited, a world leading vaccines & bio-therapeutics manufacturer and the University of Sydney Infectious Diseases Institute (Sydney ID) today announced a Memorandum of Understanding (MoU) to advance vaccine research initiatives, strengthen academic-industry partnerships and augment global efforts to…

[ranakaushal]

10th Annual Biotech Industry Conclave on Biotechnology for Humanity: Innovations Shaping a Better World

KIIT School of Biotechnology organized the 10th Biotech Industrial Conclave on “Biotechnology for Humanity: Innovations Shaping a Better World” during 23rd–24thAugust 2024. The conclave, spanning over two days, had enlightening talks, discussion and spirited interactions between experts from the biotech industry, academia, and students to foster collaboration and innovation in the field. During the inaugural session, Dr. Achyuta Samanta, Founder, KIIT & KISS, welcomed all the dignitaries and stressed upon development of strong collaboration between KIIT and biotechnology industry.

Padmashri Dr. Krishna Ella, Founder & Executive Chairman, Bharat Biotech International Limited echoed the need for close interaction between premier educational institutes and the biotech industry for inclusive growth. Dr. Ella, in his keynote address, shared his personal journey in entrepreneurship and innovation, highlighting the challenges and rewards of building a successful biotech company. He emphasized the importance of practical learning experiences for PhD students and the role of the Ella Foundation in supporting their entrepreneurial endeavors. He also stressed upon the need for vaccine development for neglected diseases.

Dr. Shilpa Gadgil, Vice President, Enzene Biosciences Ltd.; Dr. Priyabrata Pattnaik, Dy. Managing Director, Indian Immunologicals Ltd.; Raghavendra P. Rao, Principal Scientist, The Himalaya Drug Company; Dr. Ranendra N. Saha, Chief Scientific Advisor, Biophore; Dr. Sreedharala Venkata Nookaraju, Executive Vice President, Aizant Drug Research Soln. Lt;. and Dr. Prabuddha Kundu, Co-Founder & MD, Premas Biotech discussed about emerging trends in complex therapeutic biomolecules like monoclonal antibodies, novel vaccines, complex protein production processes. Mr. Dushyant Deshmukh, GM-HR, Glenmark Pharmaceuticals; Mr. Hemant Nikam, Sr Director and Head HR, Eisai Pharmaceuticals India; and Mr. Pritesh Bhatia, Associate Director HR, Jubilant Biosys Ltd. discussed about the emerging trends in human resource requirements and how students should prepare themselves to become successful biotechnology professionals.

Mr. Lalit Sisaudia, Vice President of Nutaste Group and Ms. Rosina Panda, Business Manager, Intertek spoke about food safety and the need for precision to address global food security challenges.

Dr. Emili Banerjee, Senior Genetic Counselor, Neuberg Diagnostics, Dr. Raghavendra Goud, Executive Director at PharmNXT Biotech and Mr. Ashish Dubey, Co-Founder and COO, Redcliffe Labs discussed the opportunities in molecular diagnostics in healthcare and how AI driven processes can accelerate disease detection and make healthcare accessible in the remote regions of the country. In the last session, five alumni turned entrepreneurs Mr. Pritam Dhalla, Founder, Larkai Healthcare; Mr. Akashdeep Dan, Co-Founder of Bogmalo Foods and Hospitality; Mr. Prateek Mahapatra, Director of Grow Green Consortium Pvt. Ltd.; Ms. Varsha Biswal, CEO, Trupti Dairy; and Dr. Shailesh Samal, CEO, Inflanova AB shared the memories in KSBT and how it helped them to excel in their areas of passion.

Dr. Mrutyunjay Suar, DG-Research & Innovation, and CEO, KIIT-TBI discussed about start-up innovation system in KIIT and role of Bhubaneswar City Knowledge Cluster in developing fruitful collaboration in the biotechnology sector. Dr. Jnyana Ranjan Mohanty, Registrar and Dr. Srinivas Patnaik, Dean KSBT described the academic initiatives taken for skill development of the students. Dr. Rahul Modak, Convener of the conclave thanked all the dignitaries and participants for their active participation and contribution in the conclave.

[gendronrecherche]

Bharat Biotech Unveils Oral Vaccine to Tackle Global Cholera Threat

On Tuesday, Bharat Biotech introduced an oral cholera vaccine aimed at combating the persistent global threat of cholera, particularly in areas with poor sanitation. http://dlvr.it/TChpn2

[civilmentor1]

Current affairs - 30 August 2024

1.Oral Cholera Vaccine (Hillchol) The Hindu Background: Bharat Biotech, in collaboration with Hilleman Labs, has launched Hillchol (BBV131), an oral vaccine for cholera. Global Demand: The vaccine aims to address the global shortage of Oral Cholera Vaccines (OCVs), with a demand exceeding 100 million doses per year. Dosage: Hillchol is administered in two oral doses. Clinical Trials: Phase…

[decentralvaccine]

Oral Cholera Vaccine Launched

India's Bharat Biotech said on Tuesday its oral cholera vaccine cleared a late-stage trial and that it plans a global launch, aiming to make up to 200 million doses a year amid an expanding outbreak of the disease and treatment shortages.

India's drug regulator has approved the vaccine, called Hillchol, and Bharat Biotech will apply for the World Health Organization's pre-qualification to supply to major buyers like the U.N. children's agency UNICEF, the company said.

https://www.reuters.com/business/healthcare-pharmaceuticals/indias-bharat-biotech-says-oral-cholera-vaccine-phase-3-trials-proves-safety-2024-08-27/

[pharmawalksjobs]

Job opportunity for Production department at Bharat biotech

Bharat Biotech International Limited is a versatile biotechnology firm that focuses on research, development, and production of vaccines and biotherapeutics. The company is dedicated to creating advanced vaccines and bio-therapeutics through groundbreaking and cooperative research efforts. BBIL’s cutting-edge manufacturing facility stands as the largest in the Asia-Pacific region. Join Bharat…

[rohanisblog]

India Specialty Drug Distribution Market generated a revenue of US$ 2,045.35 million in 2022 and is estimated to reach a valuation of US$ 5,997.7 million by 2031 at a CAGR of 12.93% during the forecast period 2023–2031.

Key Players in the Market Report 

Aark Pharmaceuticals

Astellas Pharma India Pvt. Ltd.

Aurobindo Pharmaceuticals

Arlak Biotech

Bharat Serums and Vaccines Limited

Biotic Healthcare

Cipla

D.Vijay Pharma

Dr. Reddy’s Laboratories Ltd

Divis Laboratories

Feron Healthcare

Gaia Pharmaceutical Trade

Glenmark Pharmaceuticals

GNova Biotech

Ikris Pharma

IMS Medi

Jay-Pharma

Lupin

Meher Distributors Pvt. Ltd.

Merck & Co., Inc.

Novartis AG

Novacare

Pax Healthcare

Prime Health

Sanify Healthcare

Serum Institute of India Pvt. Ltd.

Sun Pharmaceutical Industries Ltd.

Servocare Lifesciences

Shubham Pharmaceutical

Swisschem Healthcare

Torrent Pharmaceuticals

Vardhman Health Specialities Pvt. Ltd.

Zydus Lifesciences Limited

Intas Pharmaceuticals Ltd.

3S Corporation

Other Prominent Players

[cavenewstimes]

'Safety first', says Bharat Biotech amid AstraZeneca row

NEW DELHI: Bharat Biotech on Thursday assured Covaxin ‘s safety amid debate over Astrazeneca ‘s admission that its Covid-19 vaccine , sold as Covishield in India, could cause “rare’ side effects.The vaccine company posted a statement on X, mentioning that Covaxin was the sole Covid-19 vaccine in the government’s Covid-19 immunisation programme to have conducted efficacy trials in India. The…

[thenewsfactsnow]

India is a Front Runner to Develop Anti Zika Virus Vaccine: NTAGI Chief

India is a Front Runner to Develop Anti Zika Virus Vaccine: NTAGI Chief Dr NK Arora. #ZikaVirus #ZikaVaccine #BharatBiotech #Vaccine #Zika #Science #Research #PublicHealth

Zika Virus is on the prowl in India. NTAGI Chief Dr. NK Arora, who heads the National Technical Advisory Group on Immunization (NTAGI), stated on Tuesday that India needs to be prepared to combat the Zika virus in the event of a “outbreak.” Dr. Arora’s statement follows after a report that a 5-year-old girl from Karnataka has tested positive for the Zika virus. “Zika virus is something which is…

[ednetconsultant]

Some Basic Requirements that you need to know before applying for a Canada Study Visa

Canada continues to attract lots of international students in 2024 as well. Lots of students want to go to Canada from India for further education. There are lots of things that any student needs to know before applying for a Canada study visa. But as a student, you can't gather that much information so it is advised to visit Study abroad consultants in Delhi for Canada. The consultants will guide you and help you at every step, not only this they will let you know all the requirements related to the Canada study visa. 

To get admission to Canada you must have excellent academic scores. The study permit will be issued at the time of the arrival in Canada. Know you want to know how Indian students can study in Canada and what are the important things any student needs to know. 

What do you understand by a Canada Study Permit?

This is a type of document that is issued by the Canadian immigration government authorities and serves as permission for international students to study in Canada. Any international student can't study in Canada without this permission. 

For to get your permit for Canada you need to carry some specific documents with you. while applying for a Canada visa there are lots of important things which need to be fulfilled. 

For Canada study visas students need to carry the letter of introduction with the other important documents as well. 

Some basic eligibility criteria for a study permit in Canada. 

You need to Qualify as a fully vaccinated Traveller. In Canada, there are some accepted vaccines such as AstraZeneca/COVISHIELD, Bharat Biotech Covaxin, etc.

you need to show or you should have specific documents to show that you have adequate funds to pay your tuition fees, living expenses, return transportation for yourself, etc.

you need to show proof of your clear background with no criminal record. The student should have a police verification certificate with them. 

you need to show your medical certificates as well that you don't have any major health problems. 

when you get your college acceptance letter only after that you can apply for a study permit in Canada. 

Apart from these, there are some valid documents which are required for the visa.

The first one is a valid passport. According to the Canadian government, your passport validity covers the intended stay In Canada. Suppose you are planning to travel to Canada for a year course in September 2022 then your passport should be valid until at least September 2024. 

Acceptance letter from college and university you are going to attend. 

All the proofs of funds.

Passport-size photographs.

Immigration Medical Examination Result

English Language Proficiency Exam score is very important. 

Statement of purpose and credit card. 

so if you are planning to study in Canada or Study in the USA consultants in Delhi, you need to consult Ednetconsultants for that. You will get proper guidance regarding your admission. 

[ramtracking]

Clinical trials of first adult TB vaccine derived from human source begins [ BCG vaccine ]

Clinical trials of first adult TB vaccine derived from human source begins [News Summary] Bharat Biotech International Limited, in collaboration with Biofabri, has started a series of clinical trials in adults in the country to… India News: HYDERABAD: Bharat Biotech, based in Hyderabad, has started clinical trials of MTBVAC, the world’s first Mycobacterium… World Tuberculosis (TB) Day is marked…

[aimarketresearch]

Chikungunya Treatment Market Size, Share, Trends, Demand, Growth and Competitive Outlook

Global Chikungunya treatment Market study by Data Bridge Market Research provides details about the market dynamics affecting the Chikungunya treatment market, Market scope, Market segmentation and overlays shadow upon the leading market players highlighting the favourable competitive landscape and trends prevailing over the years.

An all-inclusive Chikungunya treatment market report enables clients to boost revenues from new and existing customer base as well as identify key trends and hidden opportunities, latest developments, market shares, and strategies that are employed by the major market players. Client or business can get aware of the impact of opportunities that are offered by the market and hence design sustainable and competitive strategies in times of rapid development. A range of definitions and classification of the Chikungunya treatment industry, applications of the Chikungunya treatment industry and chain structure are given in the credible Chikungunya treatment report.

Chikungunya treatment business document is also helpful to understand the regional analysis of the market and paradigm shift in consumer preferences. This report makes it easy to analyze various market perspectives with the help of Porter’s five forces analysis. The company profiles of all the top market players and brands with moves like product launches, joint ventures, mergers and acquisitions which in turn is affecting the sales, import, export, revenue and CAGR values are revealed in this market report. Key market dynamics of the Chikungunya treatment industry is the best part about Chikungunya treatment market research report.

Data Bridge Market Research analyses that the chikungunya treatment will exhibit a CAGR of around 7.40% for the forecast period of 2021-2028. Rising prevalence of dengue in tropical and sub-tropical regions, increased government initiatives and funding to fight against dengue, surge in the research and development activities for the development of novel drugs and therapies and increased expenditure for the development of healthcare infrastructure are the major factors attributable to the growth of chikungunya treatment market.

Access Full 350 Pages PDF Report @

Highlights of TOC:

Chapter 1: Market overview

Chapter 2: Global Chikungunya treatment Market

Chapter 3: Regional analysis of the Global Chikungunya treatment Market industry

Chapter 4: Chikungunya treatment Market segmentation based on types and applications

Chapter 5: Revenue analysis based on types and applications

Chapter 6: Market share

Chapter 7: Competitive Landscape

Chapter 8: Drivers, Restraints, Challenges, and Opportunities

Chapter 9: Gross Margin and Price Analysis

Countries Studied:

North America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)

Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)

Middle-East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)

Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

The major players covered in the chikungunya treatment market report are Merck KGaA, QIAGEN, Bio-Rad Laboratories, Danaher., Hologic, Inc., BD, Abbott, Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd, Siemens Healthcare GmbH, bioMérieux SA, Zydus Cadila, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited., Themis Bioscience GmbH, Bharat Biotech., Paradigm Biopharmaceuticals Ltd, Nano Therapeutics Pvt Ltd, Hawaii Biotech Inc. and Integral Molecular among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Browse Trending Reports:

Respiratory Polygraphs Market

Biomedical Refrigerators And Freezers Market

Digital Mobile X Ray Devices Market

Point Of Care Poc Urinalysis Market

Viral Clearance Services Market

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact Us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email: corporatesales@databridgemarketresearch.com

[decentralvaccine]

Clinical Trials Begin For Spanish TB Vaccine

Clinical trials of Spanish tuberculosis (TB) vaccine MTBVAC have begun in India.

Vaccine maker Bharat Biotech is conducting the trials in partnership with Spanish biopharmaceutical company Biofabri that is responsible for clinical and industrial development of the vaccine developed in the laboratory of the University of Zaragoza with Dr. Brigitte Gicquel of the Pasteur Institute, Paris.

MTBVAC is the only vaccine against tuberculosis in clinical trials based on a genetically modified form of the pathogen isolated from humans Mycobacterium tuberculosis which, unlike the BCG vaccine, contains all the antigens present in strains that infect humans. While the trials to evaluate the safety and immunogenicity of MTBVAC in India have begun, a pivotal safety, immunogenicity and efficacy trial is planned in 2025, Bharat Biotech said in an announcement coinciding with World Tuberculosis Day on March 24.

[nuovos00]

Cultivating Health and Harvests: India's Biotech Frontier Enriching Lives and Landscapes

In a remarkable confluence of innovation, government initiatives, and strategic investments,India is undergoing a biotech revolution that is reshaping both healthcare and agriculture. The nation’s commitment to self-reliance, as evident in initiatives like Aatmanirbhar Bharat and Make in India, has propelled it into a leading position in the global biotechnology industry. From the production of vaccines to pioneering sustainable agricultural practices, India’s biotech sector is leaving an indelible mark on the world stage.

Healthcare Breakthroughs: Aatmanirbhar Bharat in Action

Global Vaccine Supplier At the forefront of India's biotech success story is its prowess in vaccine production. The nation has evolved into a leading global vaccine supplier, exporting vaccines to over 150 countries. The government's Atma Nirbhar Bharat initiative, coupled with strategic investments in research and development, has catapulted India into the limelight during the global battle against the COVID-19 pandemic. With a competitive edge in efficacy and affordability, Indian vaccines have become a beacon of hope worldwide.

Biopharmaceutical Dominance The biopharmaceutical segment holds a lion's share of the Indian biotech industry, constituting 62% with a market value of $57.5 billion. Leveraging generics and biosimilars, Indian companies are not only meeting domestic demand but are also emerging as global players. The Union Budget 2023 further reinforced the commitment to the sector by announcing the establishment of 500 'waste to wealth' plants under the GOBARdhan scheme, showcasing a dedication to sustainability and circular economy practices.

National Biopharma Mission: Innovate in India (I3) The National Biopharma Mission: Innovate in India (I3) is a collaborative effort between the Department of Biotechnology (DBT) and the World Bank, injecting $250 million into the sector. With a vision to enhance India's technological and product development capabilities in biopharmaceuticals, I3 represents a transformative step towards self-sufficiency and global competitiveness. This infusion of funds is poised to drive innovation, entrepreneurship, and economic growth within the biopharmaceutical landscape.

Agriculture Revolution: Biotech-KISAN Paving the Way

Sustainable Agricultural Practices India's agricultural revolution is equally compelling, with a focus on sustainable practices driven by biotechnology. The Department of Biotechnology's Biotech-KISAN (Biotech Krishi Innovation Science Application Network) initiative is a game-changer, connecting farmers with scientists and institutions. With 51 hubs across the country, Biotech-KISAN empowers farmers, especially women, with information on soil health, irrigation, and new agri-technologies. This initiative goes beyond increasing yields; it fosters an environment of innovation and inclusivity in agriculture.

Organic Agricultural Land India boasts the fifth-largest area of organic agricultural land globally. The Biotech-KISAN hubs, strategically set up in 15 agro-climatic zones, contribute to the growth of sustainable agriculture. By leveraging biotechnology, these hubs address critical challenges such as soil health, water usage, and crop protection. The result is a comprehensive approach to farming that ensures long-term sustainability and environmental responsibility.

National Cold Chain Management Information System The success of India's vaccine distribution is not only about production but also about effective logistics. The National Cold Chain Management Information System plays a crucial role in maintaining the integrity of vaccines throughout the supply chain. This technology-driven system ensures that vaccines are stored and transported at optimal temperatures, contributing to the reliability of Indian vaccines on the global stage.

Bio-IT and Bio-Services: The Technological Edge

Digitization of Health Records India's emergence as an emerging hub for Bio-IT and Bio-Services is marked by its success in digitizing health records. This technological revolution has streamlined healthcare operations, providing efficient data management and accessibility to critical information. The seamless transition from paper-based systems to digital platforms is a testament to India's commitment to utilizing technology to enhance patient care and medical research.

Skilled English-Speaking Workforce India's competitive edge in Bio-IT and Bio-Services is fortified by the presence of a skilled, English-speaking workforce. With expertise in both life sciences and information technology, India offers a unique advantage for companies seeking seamless collaboration between these two disciplines. The ability to communicate effectively in English further enhances India's appeal as a preferred destination for outsourcing Bio-IT and Bio-Services.

Low-Cost Clinical Trials India's reputation as a hub for low-cost clinical trials is a game-changer in the global biotech landscape. The cost-effectiveness of conducting trials in India, coupled with a regulatory framework ensuring ethical standards, positions the country as an attractive destination for pharmaceutical and biotech companies. This favorable environment not only accelerates the drug development process but also fosters innovation in healthcare solutions.

The Global Impact The impact of India's biotech revolution extends far beyond its borders. Collaborations with global pharmaceutical giants, research institutions, and technology companies underscore India's position as a key player in shaping the future of healthcare. As the nation supplies vaccines to over 150 countries, contributes to sustainable agriculture, and leads in Bio-IT and Bio-Services, it cements its status as a global powerhouse in biotechnology.

Navigating Challenges and Shaping the Future While the biotech landscape in India is flourishing, it is not without challenges. Balancing affordability with quality, ensuring data security, and navigating the evolving regulatory landscape are ongoing endeavors. However, collaborative efforts between the government, industry stakeholders, and regulatory bodies are crucial to overcoming these challenges and shaping the future of biotechnology in India.

Conclusion: A Transformative Journey India's biotech revolution is a transformative journey that encompasses healthcare, agriculture, and technological innovation. From leading the global vaccine supply to revolutionizing sustainable agriculture and pioneering Bio-IT solutions, India is carving a niche as a hub of biotechnological excellence. Initiatives like Aatmanirbhar Bharat, Biotech-KISAN, National Biopharma Mission-I3, and others showcase the nation's commitment to innovation, self-reliance, and global leadership in the biotech arena. As India continues to shape the future of biotechnology, the world watches in anticipation of the next wave of transformative breakthroughs.

Visit: https://adypunuovos.com/programs/mba-digital-health-transformation/

[themarketinsights]

Vaccine Conjugate Market is set for a Potential Growth Worldwide: Excellent Technology Trends with Business Analysis

Latest released the research study on Global Vaccine Conjugate Market, offers a detailed overview of the factors influencing the global business scope. Vaccine Conjugate Market research report shows the latest market insights, current situation analysis with upcoming trends and breakdown of the products and services. The report provides key statistics on the market status, size, share, growth factors of the Vaccine Conjugate The study covers emerging player’s data, including: competitive landscape, sales, revenue and global market share of top manufacturers are Bharat Biotech (India), Biological E (India), CSL Limited (Australia), GlaxoSmithKline, plc. (U.K.), Merck and Company (U.S.), Neuron Biotech (U.S.), Novartis AG (Switzerland), Pfizer, Inc. (U.S.), Sanofi Pasteur (France), Serum Institute of India (India)

Free Sample Report + All Related Graphs & Charts @: https://www.advancemarketanalytics.com/sample-report/3382-global-vaccine-conjugate-market-1?utm_source=Organic&utm_medium=Vinay

Conjugate vaccines refer to those vaccines that contain bacterial capsule polysaccharide or conjugated to a protein or the antigen attached. This protein plays a vital role in enhancing the immunogenic property of the polysaccharide which helps to protect the body from microorganisms.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Southeast Asia.